Similar articles

• Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences.

  Kelishadi R, Farajian S, Mirlohi M. Kelishadi R, et al. Hepat Mon. 2013 Apr 9;13(4):e7233. doi: 10.5812/hepatmon.7233. Print 2013 Apr. Hepat Mon. 2013. PMID: 23885277 Free PMC article.
• Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study.

  Weinstein G, Zelber-Sagi S, Preis SR, Beiser AS, DeCarli C, Speliotes EK, Satizabal CL, Vasan RS, Seshadri S. Weinstein G, et al. JAMA Neurol. 2018 Jan 1;75(1):97-104. doi: 10.1001/jamaneurol.2017.3229. JAMA Neurol. 2018. PMID: 29159396 Free PMC article.
• Current treatment for non-alcoholic fatty liver disease.

  Moctezuma-Velázquez C. Moctezuma-Velázquez C. Rev Gastroenterol Mex (Engl Ed). 2018 Apr-Jun;83(2):125-133. doi: 10.1016/j.rgmx.2017.10.003. Epub 2018 Apr 11. Rev Gastroenterol Mex (Engl Ed). 2018. PMID: 29655574 Review. English, Spanish.
• [Assessment methods and research status of quality of life in patients with nonalcoholic fatty liver disease].

  Rao HY. Rao HY. Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):278-283. doi: 10.3760/cma.j.cn50113-20190719-00255. Zhonghua Gan Zang Bing Za Zhi. 2020. PMID: 32306665 Chinese.
• Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.

  Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Shiha G, et al. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):57-64. doi: 10.1016/S2468-1253(20)30213-2. Epub 2020 Nov 9. Lancet Gastroenterol Hepatol. 2021. PMID: 33181119 Review.